柔肝降脂胶囊治疗非酒精性脂肪肝疗效及对患者血脂的影响分析

发布时间：2018-10-24 15:54

【摘要】：目的:观察柔肝降脂胶囊治疗非酒精性脂肪肝疗效及对患者血脂的影响。方法:将常州市第三人民医院2015年1月~2016年6月期间收治的100例非酒精性脂肪肝患者纳入研究,分为2组,各50例。对照组给予常规药物治疗,观察组另外给予柔肝降脂胶囊。对比两组肝功能、血脂等的差异。结果:(1)观察组的总有效率为92.00%,明显高于对照组74.00%。治疗后,观察组肝功能指标谷丙转氨酶(ALT)、谷草转氨酶(AST)和谷氨酰转肽酶(γ-GT)水平分别为(45.19±4.92、38.06±4.41、57.61±4.33)U/L,均明显低于对照组(53.00±5.13、47.59±4.53、64.0±4.75)U/L。(3)治疗后,观察组血脂指标总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)水平分别为(5.25±0.44、1.61±0.15和2.86±0.27)mmol/L,均明显低于对照组(5.86±0.51、1.90±0.18和3.21±0.29)。(4)治疗后,观察组主要症状积分和肝/脾CT比值分别为(4.07±0.78分、0.89±0.13),均明显优于对照组(5.12±0.83分、0.77±0.13)。(5)治疗期间,观察组有2例(4.00%)发生不良反应,略低于对照组3例(6.00%),差异无统计学意义。结论:柔肝降脂胶囊可改善非酒精性脂肪肝患者肝功能、降低血脂,且用药安全。
[Abstract]:Objective: to observe the curative effect of Rugan Jiangzhi capsule on non-alcoholic fatty liver and its effect on blood lipid. Methods: 100 patients with non-alcoholic fatty liver admitted from January 2015 to June 2016 in the third people's Hospital of Changzhou were divided into two groups, 50 cases in each group. The control group was treated with routine medicine, and the observation group was treated with Rugan Jiangzhi capsule. The difference of liver function and blood lipid between the two groups was compared. Results: (1) the total effective rate of the observation group was 92.00, which was significantly higher than that of the control group. After treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and glutamyl transpeptidase (纬 -GT) in the observation group were (45.19 卤4.92 卤38.06 卤4.41 卤57.61 卤4.33) U / L, significantly lower than those in the control group (53.00 卤5.1347.59 卤4.53 卤64.0 卤4.75) U / L, respectively. The levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the observation group were (5.25 卤0.44v) 1.61 卤0.15 and 2.86 卤0.27 mmol/L, respectively, which were significantly lower than those in the control group (5.86 卤0.51c1.90 卤0.18 and 3.21 卤0.29). (4), respectively. The main symptom score and liver / spleen CT ratio in the observation group were (4.07 卤0.78) and (0.89 卤0.13), respectively, which were significantly better than those in the control group (5.12 卤0.83, 0.77 卤0.13). (5). Adverse reactions occurred in 2 cases (4.00%) in the observation group, slightly lower than in 3 cases (6.00%) in the control group. Conclusion: Rugan Jiangzhi capsule can improve liver function and reduce blood lipid in patients with non-alcoholic fatty liver.
【作者单位】：常州市第三人民医院;
【分类号】：R259

【参考文献】